Indivior PLC
INDV21.050USD
0.000
Market hours （ET）Quotes delayed by 15 min
2.63BMarket Cap
LossP/E TTM
More Details of Indivior PLC Company
Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
Company Info
Ticker SymbolINDV
Company nameIndivior PLC
IPO dateDec 24, 2014
CEOMr. Joseph J. (Joe) Ciaffoni
Number of employees1030
Security typeOrdinary Share
Fiscal year-endDec 24
Address234 Bath Road
CitySLOUGH
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited Kingdom
Postal codeSL1 4EE
Phone448043791090
Websitehttps://www.indivior.com/en
Ticker SymbolINDV
IPO dateDec 24, 2014
CEOMr. Joseph J. (Joe) Ciaffoni
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Vishal Kalia
Mr. Vishal Kalia
Chief Impact and Strategy Officer
Chief Impact and Strategy Officer
137.46K
+3.25%
Mr. Christian Heidbreder
Mr. Christian Heidbreder
Chief Scientific Officer
Chief Scientific Officer
132.64K
+42.74%
Ms. Cynthia (Cindy) Cetani
Ms. Cynthia (Cindy) Cetani
Chief Integrity and Compliance Officer
Chief Integrity and Compliance Officer
121.74K
--
Mr. Hillel West
Mr. Hillel West
Chief Manufacturing and Supply Officer
Chief Manufacturing and Supply Officer
121.72K
+338.91%
Mr. Joseph J. (Joe) Ciaffoni
Mr. Joseph J. (Joe) Ciaffoni
Chief Executive Officer, Director
Chief Executive Officer, Director
56.00K
--
Mr. Daniel A. (Dan) Ninivaggi, J.D.
Mr. Daniel A. (Dan) Ninivaggi, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
15.00K
--
Ms. Juliet Thompson
Ms. Juliet Thompson
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
9.63K
+150.00%
Dr. Keith Humphreys
Dr. Keith Humphreys
Non-Executive Independent Director
Non-Executive Independent Director
3.88K
+63.05%
Mr. Jeffrey W. (Jeff) Burris, Esq., J.D.
Mr. Jeffrey W. (Jeff) Burris, Esq., J.D.
Chief Legal Officer
Chief Legal Officer
760.00
--
Mr. Stuart (Tony) Kingsley
Mr. Stuart (Tony) Kingsley
Independent Non-Executive Director
Independent Non-Executive Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Vishal Kalia
Mr. Vishal Kalia
Chief Impact and Strategy Officer
Chief Impact and Strategy Officer
137.46K
+3.25%
Mr. Christian Heidbreder
Mr. Christian Heidbreder
Chief Scientific Officer
Chief Scientific Officer
132.64K
+42.74%
Ms. Cynthia (Cindy) Cetani
Ms. Cynthia (Cindy) Cetani
Chief Integrity and Compliance Officer
Chief Integrity and Compliance Officer
121.74K
--
Mr. Hillel West
Mr. Hillel West
Chief Manufacturing and Supply Officer
Chief Manufacturing and Supply Officer
121.72K
+338.91%
Mr. Joseph J. (Joe) Ciaffoni
Mr. Joseph J. (Joe) Ciaffoni
Chief Executive Officer, Director
Chief Executive Officer, Director
56.00K
--
Mr. Daniel A. (Dan) Ninivaggi, J.D.
Mr. Daniel A. (Dan) Ninivaggi, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
15.00K
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
222.00M
83.46%
Rest of World
44.00M
16.54%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Two Seas Capital LP
9.35%
Oaktree Capital Management, L.P.
8.82%
Deerfield Management Company, L.P.
8.47%
BlackRock Investment Management (UK) Ltd.
6.63%
Goldman Sachs International
6.58%
Other
60.15%
Shareholders
Shareholders
Proportion
Two Seas Capital LP
9.35%
Oaktree Capital Management, L.P.
8.82%
Deerfield Management Company, L.P.
8.47%
BlackRock Investment Management (UK) Ltd.
6.63%
Goldman Sachs International
6.58%
Other
60.15%
Shareholder Types
Shareholders
Proportion
Hedge Fund
39.97%
Investment Advisor/Hedge Fund
20.90%
Investment Advisor
14.44%
Research Firm
10.94%
Individual Investor
3.88%
Pension Fund
0.36%
Family Office
0.21%
Bank and Trust
0.20%
Venture Capital
0.04%
Other
9.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
349
120.01M
95.70%
+8.27M
2025Q1
380
119.99M
96.15%
-1.70M
2024Q4
382
116.83M
93.64%
-10.43M
2024Q3
369
117.73M
91.72%
-15.91M
2024Q2
352
119.29M
90.10%
-8.99M
2024Q1
341
129.79M
96.57%
+3.79M
2023Q4
322
124.43M
92.28%
+2.93M
2023Q3
321
114.40M
84.40%
+17.06M
2023Q2
296
115.50M
83.90%
+12.51M
2023Q1
259
96.50M
70.33%
+1.18M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Two Seas Capital LP
12.07M
9.68%
+191.47K
+1.61%
Jun 17, 2025
Oaktree Capital Management, L.P.
11.01M
8.82%
+293.23K
+2.74%
Mar 31, 2025
Deerfield Management Company, L.P.
10.57M
8.47%
+4.00M
+60.90%
Mar 31, 2025
BlackRock Investment Management (UK) Ltd.
8.27M
6.63%
+8.27M
--
Jun 27, 2025
Goldman Sachs International
8.21M
6.58%
+1.28M
+18.51%
Mar 31, 2025
Madison Avenue Partners LP
7.79M
6.25%
+2.76M
+54.85%
Mar 31, 2025
Rubric Capital Management LP
4.70M
3.77%
+1.17M
+33.20%
Apr 21, 2025
The Vanguard Group, Inc.
4.61M
3.69%
+71.54K
+1.58%
Mar 31, 2025
UBS Financial Services, Inc.
3.53M
2.83%
+2.69M
+323.54%
Mar 31, 2025
Sirovich (Matthew I.)
3.42M
2.74%
+249.62K
+7.87%
Sep 30, 2024
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares MSCI United Kingdom Small-Cap ETF
0.34%
ProShares Ultra Nasdaq Biotechnology
0.21%
Invesco Nasdaq Biotechnology ETF
0.21%
Franklin US Small Cap Multifactor Index ETF
0.17%
Vanguard US Multifactor ETF
0.16%
Invesco International BuyBack Achievers ETF
0.13%
iShares Intl Small Cap Equity Factor ETF
0.11%
SPDR S&P International Small Cap ETF
0.11%
iShares MSCI Europe Small-Cap ETF
0.1%
iShares Russell 2000 Growth ETF
0.09%
View more
iShares MSCI United Kingdom Small-Cap ETF
Proportion0.34%
ProShares Ultra Nasdaq Biotechnology
Proportion0.21%
Invesco Nasdaq Biotechnology ETF
Proportion0.21%
Franklin US Small Cap Multifactor Index ETF
Proportion0.17%
Vanguard US Multifactor ETF
Proportion0.16%
Invesco International BuyBack Achievers ETF
Proportion0.13%
iShares Intl Small Cap Equity Factor ETF
Proportion0.11%
SPDR S&P International Small Cap ETF
Proportion0.11%
iShares MSCI Europe Small-Cap ETF
Proportion0.1%
iShares Russell 2000 Growth ETF
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
